Pharvaris N.V. Ordinary Shares (PHVS) is a publicly traded Healthcare sector company. As of May 21, 2026, PHVS trades at $29.45 with a market cap of $2.01B and a P/E ratio of 0.00. PHVS moved +1.66% today. Year to date, PHVS is +18.37%; over the trailing twelve months it is +70.72%. Its 52-week range spans $11.51 to $33.33. Analyst consensus is strong buy with an average price target of $49.10. Rallies surfaces PHVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pharvaris Sees $74 Analyst Target, $132.3M Raise and 2026 HAE Data: UBS analyst set a $74 price target for Pharvaris, implying 63.2% upside from recent $31.25 levels. The company raised $132.3 million in an underwritten offering, holds €247 million cash, and targets CHAPTER-3 data in Q3 2026 with an HAE treatment NDA filing in H1 2026.
| Metric | Value |
|---|---|
| Price | $29.45 |
| Market Cap | $2.01B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $33.33 |
| 52-Week Low | $11.51 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
10 analysts cover PHVS: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.10.